Recent Advancements in Cancer RNA-interference Therapy with Nanotechnology Strategies
DOI:
https://doi.org/10.62382/jcbt.v1i2.7Keywords:
RNA-interference, siRNA, miRNA, Delivery, Targeting, Cancer, Targeted deliveryAbstract
Cancer is a global challenge, and genetics play a major role in onsets and in designing the next generation of cancer therapies. One of the key approaches is the downregulation of genes through RNA interference (RNAi) which has been proposed as a promising tool for controlling cancer-causing genes by employing a complementary base-pairing mechanism. Crucial tools in RNAi; small interfering RNA (siRNA), and microRNA (miRNA) have been extensively utilized in cancer therapy. Despite their discovery nearly two decades ago, only a handful of RNAi-based products have recently gained approval from regulatory authorities like the FDA, principally due to inherent limitations. The efficacy of RNAi therapies is significantly hindered by barriers related to absorption, distribution, metabolism, and excretion, leading to rapid elimination from the systemic circulation before reaching the cytosol of targeted cells. Nevertheless, RNAi therapeutics hold immense promise in various diseases, especially in various types of cancer. Overcoming these challenges demands the design of suitable drug delivery systems and the implementation of strategies aimed at enhancing pharmacokinetic parameters associated with RNAi therapies. Nanotechnology-based vehicles such as polymer-based nanoparticles, lipid nanoparticles, liposomes, dendrimers, and inorganic nanoparticles may serve as efficient carriers for targeting RNAi therapies to their desired sites. This review discusses the recent advances in nanotechnology strategies for RNAi delivery, with the overarching objective of facilitating effective targeting and gene silencing for the advancement of RNAi in cancer therapy.
Downloads
References
Tian Z, Liang G, Cui K, Liang Y, Wang Q, et al. Insight into the prospects for RNAi therapy of cancer. Frontiers in Pharmacology. 2021, 12, 644718.
Arora L, Narula A. Gene editing and crop improvement using CRISPR-Cas9 system. Frontiers in Plant Science. 2017, 8, 296675.
Demirci Y, Zhang B, Unver T. CRISPR/Cas9: an RNA‐guided highly precise synthetic tool for plant genome editing. Journal of Cellular Physiology. 2018, 233(3), 1844-59.
Bortesi L, Fischer R. The CRISPR/Cas9 system for plant genome editing and beyond. Biotechnology Advances. 2015, 33(1), 41-52.
Lam JK, Chow MY, Zhang Y, Leung SW. siRNA versus miRNA as therapeutics for gene silencing. Molecular Therapy-Nucleic Acids. 2015, 4(9), e252.
Filipowicz W, Jaskiewicz L, Kolb FA, Pillai RS. Post-transcriptional gene silencing by siRNAs and miRNAs. Current Opinion in Structural Biology. 2005, 15(3), 331-41.
Obi P, Chen YG. The design and synthesis of circular RNAs. Methods. 2021, 196, 85-103.
Li X, Yang L, Chen LL. The biogenesis, functions, and challenges of circular RNAs. Molecular Cell. 2018, 71(3), 428-42.
MacFarlane LA, R Murphy P. MicroRNA: biogenesis, function and role in cancer. Current Genomics. 2010, 11(7), 537-61.
Agrawal N, Dasaradhi P, Mohmmed A, Malhotra P, Bhatnagar RK, Mukherjee SK. RNA interference: biology, mechanism, and applications. Microbiology and Molecular Biology Reviews. 2003, 67(4), 657-85.
Zhang MM, Bahal R, Rasmussen TP, Manautou JE, Zhong XB. The growth of siRNA-based therapeutics: Updated clinical studies. Biochemical Pharmacology. 2021, 189, 114432.
Ali Zaidi SS, Fatima F, Ali Zaidi SA, Zhou D, Deng W, Liu S. Engineering siRNA therapeutics: challenges and strategies. Journal of Nanobiotechnology. 2023, 21(1), 381.
Gavrilov K, Saltzman WM. Therapeutic siRNA: principles, challenges, and strategies. The Yale Journal of Biology and Medicine. 2012, 85(2), 187.
Chernikov IV, Ponomareva UA, Chernolovskaya EL. Structural modifications of siRNA improve its performance in vivo. International Journal of Molecular Sciences. 2023, 24(2), 956.
Lee JW, Choi J, Kim EH, Choi J, Kim SH, et al. Design of siRNA Bioconjugates for Efficient Control of Cancer-Associated Membrane Receptors. ACS Omega. 2023, 8(39), 36435-48.
Williford JM, Wu J, Ren Y, Archang MM, Leong KW, et al. Recent advances in nanoparticle-mediated siRNA delivery. Annual Review of Biomedical Engineering. 2014, 16, 347-70.
Sajid MI, Moazzam M, Kato S, Yeseom Cho K, Tiwari RK. Overcoming barriers for siRNA therapeutics: from bench to bedside. Pharmaceuticals. 2020, 13(10), 294.
Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell. 2009, 136(4), 642-55.
Hu B, Zhong L, Weng Y, Peng L, Huang Y, et al. Therapeutic siRNA: state of the art. Signal Transduction and Targeted Therapy. 2020, 5(1), 101.
Neumeier J, Meister G. siRNA specificity: RNAi mechanisms and strategies to reduce off-target effects. Frontiers in Plant Science. 2021, 11, 526455.
Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nature reviews Drug Discovery. 2009, 8(2), 129-38.
Wang J, Lu Z, Wientjes MG, Jessie LS. Delivery of siRNA therapeutics: barriers and carriers. The AAPS Journal. 2010, 12, 492-503.
Dominska M, Dykxhoorn DM. Breaking down the barriers: siRNA delivery and endosome escape. Journal of Cell Science. 2010, 123(8), 1183-9.
Abosalha AK, Boyajian J, Ahmad W, Islam P, Ghebretatios M, et al. Clinical pharmacology of siRNA therapeutics: current status and future prospects. Expert Review of Clinical Pharmacology. 2022, 15(11), 1327-41.
Gujrati M, Malamas A, Shin T, Jin E, Sun Y, et al. Multifunctional cationic lipid-based nanoparticles facilitate endosomal escape and reduction-triggered cytosolic siRNA release. Molecular Pharmaceutics. 2014, 11(8), 2734-44.
Morales-Becerril A, Aranda-Lara L, Isaac-Olivé K, Ocampo-García BE, Morales-Ávila E. Nanocarriers for delivery of siRNA as gene silencing mediator. EXCLI Journal. 2022, 21, 1028.
Ashique S, Almohaywi B, Haider N, Yasmin S, Hussain A, et al. siRNA-based nanocarriers for targeted drug delivery to control breast cancer. Advances in Cancer Biology-Metastasis. 2022, 4, 100047.
Lee SWL, Paoletti C, Campisi M, Osaki T, Adriani G, et al. MicroRNA delivery through nanoparticles. Journal of Controlled Release. 2019, 313, 80-95.
Babu A, Muralidharan R, Amreddy N, Mehta M, Munshi A, Ramesh R. Nanoparticles for siRNA-based gene silencing in tumor therapy. IEEE Transactions on Nanobioscience. 2016, 15(8), 849-63.
Kandasamy G, Maity D. Inorganic nanocarriers for siRNA delivery for cancer treatments. Biomedical Materials. 2024, 19(2), 022001.
Mushtaq G, Hasani IW, Al-Daoud F, Unnisa A, Mutair YA, et al. Exploring nanotechnology-based approaches using miRNAs to treat neurodegenerative disorders. Turkish Journal of Biochemistry. 2023, 48(5), 446-58.
Luo X, Peng X, Hou J, Wu S, Shen J, et al. Folic acid-functionalized polyethylenimine superparamagnetic iron oxide nanoparticles as theranostic agents for magnetic resonance imaging and PD-L1 siRNA delivery for gastric cancer. International Journal of Nanomedicine. 2017, 5331-43.
Liu B, Cao W, Qiao G, Yao S, Pan S, et al. Effects of gold nanoprism-assisted human PD-L1 siRNA on both gene down-regulation and photothermal therapy on lung cancer. Acta Biomaterialia. 2019, 99, 307-19.
Liu Y, Pan Y, Cao W, Xia F, Liu B, et al. A tumor microenvironment responsive biodegradable CaCO3/MnO2-based nanoplatform for the enhanced photodynamic therapy and improved PD-L1 immunotherapy. Theranostics. 2019, 9(23), 6867.
Chaudhari R, Nasra S, Meghani N, Kumar A. MiR-206 conjugated gold nanoparticle based targeted therapy in breast cancer cells. Scientific Reports. 2022, 12(1), 4713.
Peng J, Wang R, Sun W, Huang M, Wang R, et al. Delivery of miR-320a-3p by gold nanoparticles combined with photothermal therapy for directly targeting Sp1 in lung cancer. Biomaterials Science. 2021, 9(19), 6528-41.
Yonezawa S, Koide H, Asai T. Recent advances in siRNA delivery mediated by lipid-based nanoparticles. Advanced Drug Delivery Reviews. 2020, 154, 64-78.
Kulkarni JA, Witzigmann D, Chen S, Cullis PR, van der Meel R. Lipid nanoparticle technology for clinical translation of siRNA therapeutics. Accounts of Chemical Research. 2019, 52(9), 2435-44.
Lobovkina T, Jacobson GB, Gonzalez-Gonzalez E, Hickerson RP, Leake D, et al. In vivo sustained release of siRNA from solid lipid nanoparticles. ACS Nano Journal. 2011, 5(12), 9977-83.
Oner E, Kotmakci M, Baird AM, Gray SG, Debelec Butuner B, et al. Development of EphA2 siRNA-loaded lipid nanoparticles and combination with a small‐molecule histone demethylase inhibitor in prostate cancer cells and tumor spheroids. Journal of Nanobiotechnology. 2021, 19, 1-20.
Fattore L, Cafaro G, Di Martile M, Campani V, Sacconi A, et al. Oncosuppressive miRNAs loaded in lipid nanoparticles potentiate targeted therapies in BRAF-mutant melanoma by inhibiting core escape pathways of resistance. Oncogene. 2023, 42(4), 293-307.
Shi S, Han L, Deng L, Zhang Y, Shen H, et al. Dual drugs (microRNA-34a and paclitaxel)-loaded functional solid lipid nanoparticles for synergistic cancer cell suppression. Journal of Controlled Release. 2014, 194, 228-37.
Ozpolat B, Sood AK, Lopez-Berestein G. Liposomal siRNA nanocarriers for cancer therapy. Advanced Drug Delivery Reviews. 2014, 66, 110-6.
Liu Y, Huang L. Preparation and characterization of siRNA-loaded liposomes. Design and Delivery of SiRNA Therapeutics. 2021, 2282, 159-69.
Yonenaga N, Kenjo E, Asai T, Tsuruta A, Shimizu K, et al. RGD-based active targeting of novel polycation liposomes bearing siRNA for cancer treatment. Journal of Controlled Release. 2012, 160(2), 177-81.
Haghiralsadat F, Amoabediny G, Naderinezhad S, Forouzanfar T, Helder MN, et al. Preparation of PEGylated cationic nanoliposome-siRNA complexes for cancer therapy. Artificial Cells, Nanomedicine, and Biotechnology. 2018, 46(sup1), 684-92.
Yan Y, Li XQ, Duan JL, Bao CJ, Cui YN, et al. Nanosized functional miRNA liposomes and application in the treatment of TNBC by silencing Slug gene. International Journal of Nanomedicine. 2019, 14, 3645-67.
Cui X, Song K, Lu X, Feng W, Di W. Liposomal delivery of MicroRNA-7 targeting EGFR to inhibit the growth, invasion, and migration of ovarian cancer. ACS Omega. 2021, 6(17), 11669-78.
Biswas S, Torchilin VP. Dendrimers for siRNA delivery. Pharmaceuticals. 2013, 6(2), 161-83.
Pavan GM, Posocco P, Tagliabue A, Maly M, Malek A, et al. PAMAM dendrimers for siRNA delivery: computational and experimental insights. Chemistry-A European Journal. 2010, 16(26), 7781-95.
Zhou K, Nguyen LH, Miller JB, Yan Y, Kos P, Xiong H, et al. Modular degradable dendrimers enable small RNAs to extend survival in an aggressive liver cancer model. Proceedings of the National Academy of Sciences. 2016, 113(3), 520-5.
Liu XX, Rocchi P, Qu FQ, Zheng SQ, Liang ZC, et al. PAMAM dendrimers mediate siRNA delivery to target Hsp27 and produce potent antiproliferative effects on prostate cancer cells. ChemMedChem. 2009, 4(8), 1302-10.
Dong Y, Yu T, Ding L, Laurini E, Huang Y, et al. A dual targeting dendrimer-mediated siRNA delivery system for effective gene silencing in cancer therapy. Journal of the American Chemical Society. 2018, 140(47), 16264-74.
Costa PM, Bourgognon M, Wang JT, Al-Jamal KT. Functionalised carbon nanotubes: From intracellular uptak and cell-related toxicity to systemic brain delivery. Journal of Controlled Release. 2016, 241, 200-219.
Zare H, Ahmadi S, Ghasemi A, Ghanbari M, Rabiee N, et al. Carbon nanotubes: Smart drug/gene delivery carriers. International Journal of Nanomedicine. 2021, 16, 1681-706.
Karimi M, Solati N, Amiri M, Mirshekari H, Mohamed E, et al. Carbon nanotubes part I: preparation of a novel and versatile drug-delivery vehicle. Expert Opinion on Drug Delivery. 2015, 12(7), 1071-87.
Georgakilas V, Kordatos K, Prato M, Guldi DM, Holzinger M, et al. Organic functionalization of carbon nanotubes. Journal of the American Chemical Society. 2002, 124(5), 760-1.
Podesta JE, Al‐Jamal KT, Herrero MA, Tian B, Ali‐Boucetta H, et al. Antitumor activity and prolonged survival by carbon‐nanotube‐mediated therapeutic siRNA silencing in a human lung xenograft model. Small. 2009, 5(10), 1176-85.
Koppisetti V, Sahiti B. Magnetically Modulated Drug Delivery Systems. International Journal of Drug Development and Research. 2011, 3(1), 260-6.
Minami R, Yamamoto M, Takahama S, Miyamura T, Watanabe H, et al. RCAS1 induced by HIV-Tat is involved in the apoptosis of HIV-1 infected and uninfected CD4+ T cells. Cellular Immunology. 2006, 243(1), 41-7.
Uchida Y, Ohshima T, Sasaki Y, Suzuki H, Yanai S, et al. Semaphorin3A signalling is mediated via sequential Cdk5 and GSK3β phosphorylation of CRMP2: implication of common phosphorylating mechanism underlying axon guidance and Alzheimer's disease. Genes to Cells. 2005, 10(2), 165-79.
Meda C, Plank C, Mykhaylyk O, Schmidt K, Mayer B. Effects of statins on nitric oxide/cGMP signaling in human umbilical vein endothelial cells. Pharmacological Reports. 2010, 62(1), 100-12.
Cun D, Jensen DK, Maltesen MJ, Bunker M, Whiteside P, et al. High loading efficiency and sustained release of siRNA encapsulated in PLGA nanoparticles: quality by design optimization and characterization. European Journal of Pharmaceutics and Biopharmaceutics. 2011, 77(1), 26-35.
Matta J, Maalouf R. Delivery of siRNA therapeutics: PLGA nanoparticles approach. Frontiers in Bioscience-Scholar. 2019, 11(1), 56-74.
Ragelle H, Riva R, Vandermeulen G, Naeye B, Pourcelle V, et al. Chitosan nanoparticles for siRNA delivery: optimizing formulation to increase stability and efficiency. Journal of Controlled Release. 2014, 176, 54-63.
Jensen DMK, Cun D, Maltesen MJ, Frokjaer S, Nielsen HM, et al. Spray drying of siRNA-containing PLGA nanoparticles intended for inhalation. Journal of Controlled Release. 2010, 142(1), 138-45.
Zhou J, Patel TR, Fu M, Bertram JP, Saltzman WM. Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors. Biomaterials. 2012, 33(2), 583-91.
Piao S, Lee I, Kim S, Park H, Nagar H, et al. CRIF1 siRNA-Encapsulated PLGA Nanoparticles Suppress Tumor Growth in MCF-7 Human Breast Cancer Cells. International Journal of Molecular Sciences. 2023, 24(8), 7453.
Risnayanti C, Jang YS, Lee J, Ahn HJ. PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer. Scientific Reports. 2018, 8(1), 7498.
Byeon Y, Lee JW, Choi WS, Won JE, Kim GH, et al. CD44-targeting PLGA nanoparticles incorporating paclitaxel and FAK siRNA overcome chemoresistance in epithelial ovarian cancer. Cancer Research. 2018, 78(21), 6247-56.
Khan AA, Alanazi AM, Jabeen M, Chauhan A, Ansari MA. Therapeutic potential of functionalized siRNA nanoparticles on regression of liver cancer in experimental mice. Scientific Reports. 2019, 9(1), 15825.
Chaichian S, Kashi AM, Tehermanesh K, Mahabadi VP, Minaeian S, et al. Effect of PLGA Nanoparticle-Mediated Delivery of miRNA 503 on The Apoptosis of Ovarian Endometriosis Cells. Cell Journal (Yakhteh). 2022, 24(11), 697.
Cai C, Xie Y, Wu L, Chen X, Liu H, et al. PLGA-based dual targeted nanoparticles enhance miRNA transfection efficiency in hepatic carcinoma. Scientific Reports. 2017, 7(1), 46250.
Satya Prakash MM, inventor; NANORA PHARMA INC., assignee. METHODS OF DELIVERING ANIONIC AGENTS IN VIVO USING NON-VIRAL NANOPARTICLE-BASED DELIVERY SYSTEMS. US patent US 11, 766, 486 B2. 2023 September 26, 2023.
Gaur S, Wen Y, Song JH, Parikh NU, Mangala LS, et al. Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy. Oncotarget. 2015, 6(30), 29161.
Cosco D, Cilurzo F, Maiuolo J, Federico C, Di Martino MT, et al. Delivery of miR-34a by chitosan/PLGA nanoplexes for the anticancer treatment of multiple myeloma. Scientific Reports. 2015, 5(1), 17579.
Heidari R, Khosravian P, Mirzaei SA, Elahian F. siRNA delivery using intelligent chitosan-capped mesoporous silica nanoparticles for overcoming multidrug resistance in malignant carcinoma cells. Scientific Reports. 2021, 11(1), 20531.
Sun P, Huang W, Jin M, Wang Q, Fan B, et al. Chitosan-based nanoparticles for survivin targeted siRNA delivery in breast tumor therapy and preventing its metastasis. International journal of Nanomedicine. 2016, 4931-4.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Journal of Cancer Biomoleculars and Therapeutics
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
